| 1.77 0.2 (12.74%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.36 |
1-year : | 2.77 |
| Resists | First : | 2.02 |
Second : | 2.38 |
| Pivot price | 1.71  |
|||
| Supports | First : | 1.46 |
Second : | 1.21 |
| MAs | MA(5) : | 1.63 |
MA(20) : | 1.79 |
| MA(100) : | 1.41 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 16.9 |
D(3) : | 11.5 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 3.11 | Low : | 0.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HOWL ] has closed below upper band by 39.9%. Bollinger Bands are 22.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.84 | 1.84 - 1.85 |
| Low: | 1.57 - 1.58 | 1.58 - 1.59 |
| Close: | 1.75 - 1.77 | 1.77 - 1.79 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Thu, 23 Oct 2025
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Wed, 08 Oct 2025
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com
Wed, 08 Oct 2025
Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan
Mon, 06 Oct 2025
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Mon, 06 Oct 2025
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Fri, 03 Oct 2025
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 49.1 (%) |
| Shares Short | 856 (K) |
| Shares Short P.Month | 848 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.1 % |
| Return on Equity (ttm) | -100.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.15 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -1.08 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|